New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Check below for free stories on A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
September 18, 2014
11:55 EDTCVSRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
September 17, 2014
18:29 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:01 EDTAAgilent board approves separation of Keysight, declares special dividend
Subscribe for More Information
16:57 EDTAAgilent creates new group for services, consumables
Subscribe for More Information
16:55 EDTAAgilent announces Mike McMullen to succeed Bill Sullivan as CEO in March 2015
Subscribe for More Information
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
06:18 EDTSNYSanofi, MyoKardia announce collaboration
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:33 EDTSNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:26 EDTRUltima Media to hold a conference
Subscribe for More Information
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
09:59 EDTCVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:45 EDTBSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:24 EDTCVSCVS Health upgraded at Cowen
Subscribe for More Information
06:07 EDTCVSCVS Health upgraded to Outperform from Market Perform at Cowen
September 12, 2014
15:03 EDTBSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
14:03 EDTAKeysight enters into manufacturing test license agreement with Broadcom
Subscribe for More Information
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:49 EDTRLongbow to hold a conference
Subscribe for More Information
07:28 EDTESVPareto to hold a conference
21st Annual Oil & Offshore Conference to be held in Oslo, Norway on September 10-11.
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
07:04 EDTWBMDWebMD announces preliminary results of tender offer
WebMD Health announced the preliminary results of its tender offer to purchase up to 2,000,000 shares of its common stock at a price of $48.50 per share, which expired at 5:00 p.m., New York City time, on September 9. Based on the preliminary count by American Stock Transfer & Trust Company, the Depositary for the tender offer, approximately 6.3 million shares of common stock were properly tendered and not withdrawn, including: approximately 1.3 million shares that were tendered through notice of guaranteed delivery; and approximately 1.1 million shares that were conditionally tendered by stockholders and for which the determination whether the applicable conditions were met will be made following the verification process described below. Accordingly, WebMD expects to accept for purchase a total of 2,000,000 shares at a purchase price of $48.50 per share, for an aggregate purchase price of $97M. Since the offer was oversubscribed, the number of shares that WebMD will purchase from each tendering shareholder will be pro-rated. Based upon the preliminary count and including all shares conditionally tendered, WebMD estimates that the pro-ration factor would be approximately 31.5%.
September 9, 2014
08:34 EDTWBMDWebMD to benefit from Apple initiatives, says RBC Capital
RBC Capital expects WebMD (WBMD) to benefit from Apple's (AAPL) launch of initiatives in the consumer health IT market. The firm believes that Apple's efforts in this area will provide more publicity for WebMD. RBC Capital keeps a $70 price target and Top Pick rating on WebMD.
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
10:06 EDTAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AIG (AIG) initiated with a Buy at Citigroup... Agilent (A) initiated with an Equal Weight at Morgan Stanley... Altisource Residential (RESI) initiated with a Neutral at JPMorgan... AngloGold (AU) initiated with an Overweight at JPMorgan... Arista Networks (ANET) initiated with an Outperform at FBN Securities... C1 Financial (BNK) initiated with a Buy at Wunderlich... Cherokee (CHKE) initiated with a Buy at Roth Capital... ContraFect (CFRXU) initiated with a Buy at Maxim... DRDGOLD (DRD) initiated with an Underweight at JPMorgan... Enable Midstream (ENBL) initiated with an Equal Weight at Morgan Stanley... Enservco (ENSV) initiated with an Outperform at Northland... GoPro (GPRO) initiated with an Outperform at FBN Securities... Gold Fields (GFI) initiated with an Overweight at JPMorgan... Gulfport Energy (GPOR) initiated with an Equal Weight at Morgan Stanley... Harmony Gold (HMY) initiated with a Neutral at JPMorgan... Illumina (ILMN) initiated with an Equal Weight at Morgan Stanley... LINN Energy (LINE) reinstated with an Outperform at Credit Suisse... LinnCo (LNCO) reinstated with an Outperform at Credit Suisse... Randgold (GOLD) initiated with a Neutral at JPMorgan... Rentrak (RENT) initiated with a Buy at Needham... Rice Energy (RICE) initiated with an Accumulate at KLR Group... SanDisk (SNDK) initiated with an Outperform at FBN Securities... Seadrill (SDRL) initiated with a Sell at Canaccord... Tesla (TSLA) initiated with an Outperform at FBN Securities... Thermo Fisher (TMO) initiated with an Overweight at Morgan Stanley... Waters (WAT) initiated with an Underweight at Morgan Stanley... Whiting Petroleum (WLL) initiated with an Equal Weight at Morgan Stanley.
10:00 EDTSPWSPX Corp. to host analyst and investor meeting
Analyst and Investor Meeting to be held in Milwaukee on September 9 at 9 am. Webcast Link
08:01 EDTCVSCVS Health completes purchase of Navarro Discount Pharmacy
Subscribe for More Information
07:35 EDTAAgilent initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
07:26 EDTBSX, CVSMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
07:04 EDTESVEnsco September volatility increases as shares pull back
Subscribe for More Information
September 5, 2014
08:01 EDTSPWSPX Corp. awarded $50M order to provide ClearSky for China facility
Subscribe for More Information
September 4, 2014
10:02 EDTRRyder announces partnership with Anheuser-Busch
Ryder System (R) announced that it is partnering with Anheuser-Busch (BUD) to replace the beer company’s 66 diesel tractor fleet in Houston with Compressed Natural Gas powered engines. Anheuser-Busch added an environmental goal to reduce carbon emissions in its logistics operations from network planning, transportation, and warehousing by 15% by the end of 2017. Once fully installed, the company estimates it will secure significant savings.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use